CD27 antibody (AA 28-170)

Catalog No. ABIN7477407

This Mouse Monoclonal antibody specifically detects CD27 in IHC. It exhibits reactivity toward Human.

Quick Overview for CD27 antibody (AA 28-170) (ABIN7477407)

Target: CD27 (CD27 Molecule (CD27))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD27 antibody is un-conjugated

Application: Immunohistochemistry (IHC)

Clone: MSVA-027M

Product Details anti-CD27 Antibody

Binding Specificity: AA 28-170

Immunogen: Recombinant human CD27 protein fragment (aa 28-170) (exact sequence is proprietary)

Isotype: IgG

Application Details

Application Notes: IHC 1:100-1:200

Comment:

Positive Control: Tonsil: A strong, membranous staining should be seen in the majority of interfollicular lymphocytes but also in a fraction of lymphocytes in the germinal centres and the mantle zone.

Negative Control: Tonsil: CD27 staining should be absent in all epithelial cells and a fraction of lymphocytes.

Protocol: Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121 °C in pH 7,8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:150 at 37 °C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer's directions.

Restrictions: For Research Use only

Handling

Format: Liquid

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non- hazardous.

Target Details for CD27

Target: CD27 (CD27 Molecule (CD27))

Alternative Name: CD27

Background: LPFS2, S152, T cell activation antigen S152, T-cell activation antigen CD27, T14, TNFRSF7, TNFSF7, Tp55, Tumor necrosis factor receptor superfamily member 7,CD27 antibody validated for immunohistochemistry on 76 different Normal Tissues

UniProt: P26842

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints